"Ozempic dupe" TikTok claims: what the science actually shows

What did @karlysmiles actually say?

Honestly, this one is hard to fact-check in the traditional sense because the transcript is largely incoherent. @karlysmiles claims to have found "a dupe for the pancake" and says she won't "gatekeep" it because she wants "all my girls to be skinny." She then reveals something she calls a "zumpy dupe" and mentions being "in a color deficit." That's essentially the whole claim.

The video caption promises a "dupe for Ozempic" to 206,000 viewers, which is the real problem here. The caption sets a concrete medical expectation that the transcript never actually fulfills. We don't know what product she's referencing. We don't know the dose, the mechanism, or whether it's a supplement, a compounded drug, or something else entirely. She never names it clearly. That ambiguity isn't a minor gap. It's the entire substance of the claim.

Does the science back this up?

There is no supplement, over-the-counter product, or lifestyle hack that replicates the clinical weight-loss outcomes of semaglutide. Full stop. The claim of an "Ozempic dupe" is not supported by current evidence for any non-prescription alternative.

Semaglutide works as a GLP-1 receptor agonist, binding to receptors in the pancreas and brain to slow gastric emptying, reduce appetite, and improve insulin sensitivity. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed participants on 2.4mg weekly semaglutide lost a mean 14.9% of body weight over 68 weeks. No supplement has come close to replicating this mechanism or these outcomes in peer-reviewed trials. Products like berberine are sometimes marketed this way, but a 2023 meta-analysis (Xiong et al., Frontiers in Pharmacology) found berberine produced modest weight effects, nowhere near GLP-1 analog outcomes. The "dupe" framing misleads people into thinking equivalency exists when it does not.

What did they get wrong (or right)?

She got almost everything wrong, though mostly by omission rather than explicit false claims. The caption does the heaviest lifting of the misinformation. Calling anything an "Ozempic dupe" implies clinical equivalence, which no current non-prescription product can claim. That framing is irresponsible regardless of what she was actually holding.

The "color deficit" comment likely refers to a caloric deficit, which is a real and legitimate component of weight management. If that's what she meant, fine. A caloric deficit is supported by decades of research and is actually part of how GLP-1 medications work in practice: they make it easier to eat less. But a caloric deficit alone does not replicate GLP-1 receptor agonism. Conflating the two is misleading. If she was recommending a specific supplement as an Ozempic equivalent, that claim is inaccurate and potentially harmful. People who need semaglutide for metabolic or glycemic reasons cannot substitute it with a trending product a TikToker won't even name properly.

What should you actually know?

The term "Ozempic dupe" is a marketing phrase, not a clinical category. Nothing currently available without a prescription replicates the mechanism or outcomes of GLP-1 receptor agonists like semaglutide or tirzepatide. Anyone telling you otherwise is either misinformed or selling something.

There are legitimate compounded versions of semaglutide available through licensed telehealth providers during shortage periods, but these are not "dupes." They are regulated compounded drugs that require a prescription, clinical evaluation, and ongoing monitoring. The FDA has been clear that compounded semaglutide is not the same as FDA-approved Wegovy or Ozempic, and the agency has taken action against illegitimate compounders. If you're interested in GLP-1 therapy, talk to a licensed provider who can evaluate whether it's appropriate for you, discuss real risks like nausea, pancreatitis risk, and thyroid concerns, and prescribe through a legitimate channel. Don't take weight-loss advice from a video where the product is never named and the science is never cited.

• GLP-1 receptor agonists require a prescription and medical oversight.
• No supplement has demonstrated equivalent weight-loss outcomes to semaglutide in clinical trials.
• Compounded semaglutide is not an FDA-approved equivalent to brand-name drugs.
• "Caloric deficit" is not a dupe for a GLP-1 medication, though it is part of the weight-loss equation.